ID :
77090
Wed, 08/26/2009 - 18:02
Auther :
Shortlink :
http://m.oananews.org//node/77090
The shortlink copeid
Thailand's H1N1 vaccine trial gets go-ahead
BANGKOK, Aug 26 (TNA) – The Government Pharmaceutical Organisation (GPO) will go ahead with its swine flu vaccine trials with seed virus from Russia although academics have advised caution regarding mutation of the virus, according to Dr Witit Artavatkun, GPO managing director.
Genetic changes have been found in positions that are not significant, he said, so the trials can continue with the seed virus from Russia. Consequently there is no need to import further seed virus from China, he said.
The live attenuated virus has been placed in 1,270 bottles, with each bottle containing one dose or 0.7 millilitres. It will be tested to make sure it is in a germ-free condition before being sent to be used in animal and human trials.
Speaking about a location for the vaccine pharmaceuticals laboratory for full production of the vaccine, he said the working committee in charge of producing the anti-A(H1N1) vaccine planned to upgrade the Science Park at King’s Mongkut’s University of Technology Thonburi (Bangkuntien Campus).
Production capacity there can reach up to ten times higher than the capacity of the laboratory at Silpakorn University, which is being used to produce vaccine for the trial.
About 150 million baht is needed to upgrade the Science Park, which will be able to produce enough vaccine for two-thirds of Thailand’s populace.
The budget will be sought from the World Health Organization (WHO), Dr Witit said. (TNA)
Genetic changes have been found in positions that are not significant, he said, so the trials can continue with the seed virus from Russia. Consequently there is no need to import further seed virus from China, he said.
The live attenuated virus has been placed in 1,270 bottles, with each bottle containing one dose or 0.7 millilitres. It will be tested to make sure it is in a germ-free condition before being sent to be used in animal and human trials.
Speaking about a location for the vaccine pharmaceuticals laboratory for full production of the vaccine, he said the working committee in charge of producing the anti-A(H1N1) vaccine planned to upgrade the Science Park at King’s Mongkut’s University of Technology Thonburi (Bangkuntien Campus).
Production capacity there can reach up to ten times higher than the capacity of the laboratory at Silpakorn University, which is being used to produce vaccine for the trial.
About 150 million baht is needed to upgrade the Science Park, which will be able to produce enough vaccine for two-thirds of Thailand’s populace.
The budget will be sought from the World Health Organization (WHO), Dr Witit said. (TNA)
